AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Guggenheim Initiates Coverage on Urogen Pharma with Buy Rating
ByAinvest
Wednesday, Aug 20, 2025 5:36 am ET1min read
Urogen Pharma (URGN) received a new rating from Guggenheim analyst Kelsey Goodwin, who initiated coverage with a Buy rating and set a price target of $36.00. Goodwin has a 4-star rating with an average return of 36.4% and a 68.42% success rate. The company's shares closed at $19.40. URGN market cap is $911.9M and has a P/E ratio of -5.85. Corporate insider activity shows negative sentiment with an increase in insiders selling their shares over the past quarter.
Urogen Pharma Ltd. (URGN), an Israel-based biopharmaceutical company, has received a new rating from Guggenheim analyst Kelsey Goodwin. Goodwin initiated coverage with a Buy rating and set a price target of $36.00. Goodwin, who holds a 4-star rating with an average return of 36.4% and a 68.42% success rate, believes that Urogen Pharma's innovative technologies hold significant potential in the treatment of cancers and urologic diseases [2].Urogen Pharma's shares closed at $19.40 on July 2, 2025. The company's market capitalization stands at $911.9 million, and its P/E ratio is -5.85. The company has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that enhances the therapeutic profiles of existing drugs. Its lead product candidates, MitoGel (UGN-101) and VesiGel (UGN-102), are formulated using this technology [1].
However, corporate insider activity indicates negative sentiment, with an increase in insiders selling their shares over the past quarter. This suggests that insiders may have concerns about the company's future prospects or recent developments.
Urogen Pharma's recent developments, including Goodwin's positive rating, could attract more investors. However, the negative insider activity and the company's high valuation suggest caution. Investors should closely monitor the company's progress and insider activity to make informed decisions.
References:
[1] https://investors.urogen.com/stock-information/stock-quote-chart
[2] https://www.marketscreener.com/news/piper-sandler-initiates-urogen-pharma-at-overweight-with-36-price-target-ce7c51ddd981f421
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet